Apr 27, 2022 / 07:30PM GMT
Mayank Mamtani - B. Riley Securities, Inc. - Analyst
Good afternoon, everyone. This is Mayank Mamtani, senior biotech analyst. We welcome back everyone to join us for our next fireside chat with Lineage Therapeutics CEO, Brian Culley. I appreciate you making the time off your busy schedule to be part of the conference. And also, I have to congratulate you for the recent progress you've had on the strategic partnership with Roche and Genentech for your dry AMD cell therapy program.
Before we get into the nitty-gritty of what led to that collaborations -- some of the data and what that sort of means for your pipeline -- but I think it would be helpful if you could talk at a high level about Lineage: how should one think about the company on the heels of a transaction like that and then also, some of your pipeline programs that are emerging. Brian?
Brian Culley - Lineage Cell Therapeutics, Inc. - CEO
Thanks, Mayank. I'm happy to be here. Thanks also to the whole B. Riley team. So yeah, look, it was wonderful to be able to partner our lead program with
Lineage Cell Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers